Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloRx in Osteoporosis
NCT05152381Phase 1Withdrawn
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Dec 2022
- Primary completion
- Apr 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AlloRx in osteoporosis, sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Safety (adverse events) at 4 years. Planned start Dec 2022; status: withdrawn.
02
Drugs
AlloRx
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT05152381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05152381.